Anxinsec Highlighted An Innovative and All-in-one Solution for Endpoint and Workload Protection at X-LABS Stage.

Anxinsec Highlighted An Innovative and All-in-one Solution for Endpoint and Workload Protection at X-LABS Stage.

Dubai, United Arab Emirates — ANXINSEC is participating in the GISEC Global 2023, the leading gathering ground for the cybersecurity community worldwide. As a leading brand of memory security, Anxinsec shares insights about advanced threats and introduces “An innovative and all-in-one solution for endpoint and workload protection.” “0-day vulnerabilities have increased by 56% or more, every single advanced threat can cost $2.4 million to the victims; intrusion success rate has reached 80%; new types of attacks have spiked globally by 400% in 2022——Advanced threats have become a favorite of attackers…

Check Point® Software Technologies Enhances Endpoint Security with Intel vPro Platform

Check Point® Software Technologies Enhances Endpoint Security with Intel vPro Platform

Bolstering Check Point Harmony Endpoint with Intel® Threat Detection Technology enables customers to take advantage of expanded protection surface and processor level security Dubai, United Arab Emirates Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, has announced an extended collaboration with Intel Corporation to offer enhanced anti-ransomware capabilities for Check Point Harmony’s customers. As ransomware attacks increase in scale and sophistication, integrating the Intel vPro(R) platform’s Threat Detection Technology (TDT) within Check Point Harmony Endpoint helps provide enterprises with processor level anti-ransomware security at…

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

PARIS — Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens. Further details about the OS benefit and other results from the primary analysis of the global SUNLIGHT trial will be presented at an upcoming international scientific conference. “Findings from the SUNLIGHT trial could potentially…

Acronis recognized as a high performer in the Canalys Endpoint Security Vendor Performance Index for Q1 2022

Acronis recognized as a high performer in the Canalys Endpoint Security Vendor Performance Index for Q1 2022

UNITED ARAB EMIRATES, Dubai: Acronis, the global leader in cyber protection, announced today it has been recognized as a High Performer in the Canalys Endpoint Security Vendor Performance Index for Q1 2022. The company, praised for being a cyber protection pioneer, realized an 18.8 percent growth in revenue compared to the first quarter of 2021. Canalys, a leading global technology market analyst firm, releases the quarterly Endpoint Security Vendor Performance Index research to highlight market share and trends within the endpoint protection industry. Specifically, it “assesses vendor performance, in terms…